RCT | Sparsentan reduces proteinuria in patients with IgA nephropathy
3 Apr, 2023 | 13:35h | UTCSparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
PROTECT (Interim results): Sparsentan reduces proteinuria in patients with IgA Nephropathy (IgAN)#ISNWCN ?? #Nephpearls#VisualAbstract by @dakidneydochttps://t.co/ViW9YncwI6 pic.twitter.com/zEGRSY8N3x
— Edgar V. Lerma ?? (@edgarvlermamd) April 1, 2023